Ester-E product linked to cholesterol reduction

15/04/05 Zila, Inc. has commented on a report by Phosphagenics Limited that suggests the Ester-E product may reduce cholesterol. In the Phosphagenics animal study, the Ester-E product technology significantly reduced levels of LDL-C (so-called bad cholesterol) in the blood while regular vitamin E had no effect.

Zila Nutraceuticals, a wholly owned subsidiary of Zila, has an exclusive license to the patented Phosphagenics' vitamin E technology within the dietary supplement category in the United States, Canada and Indonesia and has the right of first refusal to other global markets. Zila Nutraceuticals produces and distributes the product as Ester-E.

The study results show that the unique Ester-E form of vitamin E lowered bad cholesterol concentrations in blood by up to 40%. These results suggest that Ester-E may have the potential to yield healthier levels of total cholesterol, triglycerides and LDL-C in humans. The animal model chosen for the trials is commonly used in cardiovascular research as it mimics many of the properties observed clinically in humans.